{
    "2020-06-23": [
        [
            {
                "time": "2018-03-15",
                "original_text": "Should You Invest in the VanEck Vectors Pharmaceutical ETF (PPH)?",
                "features": {
                    "keywords": [
                        "VanEck",
                        "Vectors",
                        "Pharmaceutical",
                        "ETF",
                        "PPH"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2019-04-22",
                "original_text": "AbbVie's (ABBV) sBLA for Botox Gets Acceptance From FDA",
                "features": {
                    "keywords": [
                        "AbbVie",
                        "ABBV",
                        "Botox",
                        "FDA",
                        "sBLA"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2020-07-10",
                "original_text": "IMBRUVICA® (ibrutinib) Seeks to Expand U.S. Label with Long-Term Data in Waldenström's Macroglobulinemia (WM)",
                "features": {
                    "keywords": [
                        "IMBRUVICA",
                        "ibrutinib",
                        "U.S.",
                        "Label",
                        "Long-Term",
                        "Data",
                        "Waldenström's",
                        "Macroglobulinemia",
                        "WM"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            }
        ]
    ]
}